The current treatment of incurable NSCLC patients consists of systemic chemotherapy (CT), radiotherapy (RT), therapies targeting oncodrivers (e.g., epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKI) or the immune system (immunotherapies), in addition to best supportive care (e.g., pain relief). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.